GLP-1 medications and weight loss: what you need to know
Semaglutide, tirzepatide, and related medications are changing how many patients think about weight. Here is an honest look at what they do, who they may help, and what to watch for.
What exactly is a GLP-1?
GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally produces after you eat. It tells your pancreas to release insulin, slows how quickly your stomach empties, and signals your brain that you have eaten enough.
GLP-1 receptor agonist medications mimic and amplify those signals. For many people, that means smaller portions feel satisfying and food noise becomes quieter. Tirzepatide also activates GIP receptors, which may help explain why it has produced greater weight loss in some clinical trials.
The advantages are real
- Semaglutide has shown average weight loss of about 15% of body weight over 68 weeks in clinical trials.
- Tirzepatide has shown average weight loss of 20% to 22% of body weight in some trials.
- The SELECT trial showed semaglutide reduced major cardiovascular events by 20% in people with obesity and existing heart disease.
- These medications can also improve blood sugar control, blood pressure, and triglycerides for the right patient.
Why weight health matters for rheumatology patients
Excess weight can drive systemic inflammation and add mechanical stress to painful joints. In rheumatology care, weight health is part of the larger conversation about inflammation, function, treatment response, and quality of life.
Inflammation
Adipose tissue is active tissue. It can secrete pro-inflammatory cytokines, including TNF-alpha and IL-6.
Joint load
Meaningful weight loss may reduce the load on painful joints and support day-to-day mobility.
Treatment planning
Weight, inflammation, muscle strength, sleep, nutrition, and medication response all belong in the same care conversation.
Side effects to know and take seriously
- GI symptoms such as nausea, vomiting, diarrhea, constipation, and acid reflux are common, especially during dose increases.
- Rapid weight loss can include loss of lean muscle mass, which matters for joint stability, fall prevention, and function.
- GLP-1 medications can worsen or unmask gastroparesis in susceptible patients.
- Pancreatitis is rare but serious and can cause severe abdominal pain radiating to the back with sudden nausea, vomiting, or fever.
- These medications carry a warning related to medullary thyroid carcinoma and are contraindicated with personal or family history of MTC or MEN2.
Use them as part of a full plan
Slow dose escalation is often better tolerated. Protein intake and resistance training are also important, especially for patients with inflammatory arthritis, fibromyalgia, or anyone over 50.
Tell your doctor promptly about severe or persistent abdominal pain, persistent vomiting, vision changes, significant muscle weakness, unusual fatigue, or any lump or swelling in the neck.
Who may be a candidate?
GLP-1 medications are generally considered for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as type 2 diabetes, hypertension, high cholesterol, or obstructive sleep apnea.
Who should use caution?
They are generally not appropriate for patients with a personal or family history of medullary thyroid carcinoma or MEN2, severe gastroparesis, pregnancy or plans for pregnancy, and some patients with a history of pancreatitis. Discuss your full medical and family history with the prescribing clinician.
These medications are powerful tools, not stand-alone cures
GLP-1 medications can be a genuine clinical advance for the right patient, but they work best with nutrition, protein intake, resistance exercise, sleep, stress management, and appropriate monitoring. If you are curious whether a GLP-1 medication might be appropriate for you, bring it up at your next visit.